乳腺癌放疗后淋巴水肿正常组织并发症概率模型的开发与验证
研究回顾性纳入两家独立机构的1345例接受放疗的乳腺癌患者,建立并验证预测淋巴水肿的多变量正常组织并发症概率(NTCP)模型。模型纳入腋窝淋巴结清扫数目和腋窝-胸外侧血管交汇处(ALTJ)接受≥35 Gy(2 Gy分次等效剂量)的体积,内部验证AUC 0.89,外部验证AUC 0.83,校准良好。
要点
- 模型纳入淋巴结清扫数目和ALTJ V35两个因素,内部验证AUC 0.89、外部验证AUC 0.83。
- 大分割方案AUC 0.70,容积旋转调强放疗AUC 0.69,模型性能可接受。
- 全队列中位随访78.7个月,97例(7.2%)发生淋巴水肿。
核心结论
- 研究首次开发并验证了预测乳腺癌放疗后淋巴水肿发生率的多变量NTCP模型,内部验证和完全独立外部验证均显示优秀性能和稳健性。
- 该多变量模型对不同治疗方式和分次方案的淋巴水肿预测稳健可靠。
- 淋巴结清扫数目和ALTJ V35是影响放疗后淋巴水肿的最重要因素。
研究设计与样本
- 回顾性研究,纳入2家独立机构共1345例接受放疗的乳腺癌患者。
- 训练队列为机构A的368例,均接受三维适形外照射放疗,2 Gy/次。
- 外部验证队列为机构B的977例,接受三维适形外照射放疗或容积旋转调强放疗,分次为1.8-2.0 Gy/次或2.67 Gy/次。
- 勾画腋窝-胸外侧血管交汇处(ALTJ),利用剂量学和临床参数构建多变量模型,并进行全面内部和外部验证。
主要发现
- 全队列中位随访78.7个月,97例(7.2%)发生淋巴水肿。
- 多变量模型纳入淋巴结清扫数目和ALTJ接受≥35 Gy(2 Gy分次等效剂量)的体积(ALTJ V35),内部和外部验证中预测值与观察值一致性良好(Hosmer-Lemeshow P值>.05)。
- 内部验证AUC为0.89,负对数似然值为0.19;外部验证AUC为0.83,负对数似然值为0.19。
- 大分割方案AUC为0.70,容积旋转调强放疗AUC为0.69。
- 淋巴结清扫数目和ALTJ V35是影响放疗后淋巴水肿的最重要因素。
关键数值与推荐
- 模型预测变量为淋巴结清扫数目和ALTJ V35(ALTJ接受≥35 Gy 2 Gy分次等效剂量的体积)。
- 内部验证AUC 0.89,外部验证AUC 0.83;Hosmer-Lemeshow P值>.05。
- 大分割方案AUC 0.70,容积旋转调强放疗AUC 0.69。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and test a multivariable normal tissue complication probability (NTCP) model predicting lymphedema in patients with breast cancer receiving radiation therapy. METHODS AND MATERIALS: We retrospectively reviewed 1345 patients with breast cancer who received radiation therapy from 2 independent institutions. The patients were divided into a training cohort (institution A, n = 368, all treated with 3-dimensional conformal external beam radiation therapy [RT] with 2 Gy/fraction) and an external validation cohort (institution B, n = 977, treated either with 3-dimensional conformal external beam RT or with volumetric modulated RT and either with 1.8-2.0 Gy/fraction or with 2.67 Gy/fraction). Axillary-lateral thoracic vessel juncture (ALTJ) was delineated. The multivariable model was generated using dosimetric and clinical parameters. The performance of the model was comprehensively validated internally and externally. RESULTS: During a median follow-up of 78.7 months for the entire cohort, 97 patients (7.2%) developed lymphedema. The multivariable model that took into account the number of lymph nodes dissected, as well as the volume of the ALTJ receiving a dose ≥35 Gy equivalent doses in 2-Gy fractions (ALTJ V35), showed good agreement between predicted and observed results for both internal and external validation (Hosmer-Lemeshow P value > .05). The area under the receiver operating characteristic curve (AUC) and negative log-likelihood values for the multivariable NTCP model were 0.89 and 0.19 in internal validation and 0.83 and 0.19 in external validation. In addition, the multivariable model performance was acceptable for hypofractionated regimens (AUC 0.70) and volumetric modulated arc therapy (AUC 0.69). The number of lymph nodes dissected and ALTJ V35 were found to be the most important factors influencing lymphedema after radiation therapy. CONCLUSIONS: We first developed and validated the multivariable NTCP model for the lymphedema incidence in patients with breast cancer after radiation therapy. The multivariable NTCP model showed excellent performance and robustness in predicting lymphedema in both internal and completely independent external validations. The multivariable model for lymphedema prediction was robust and reliable for different treatment modalities and fractionation regimens.
引用
- Park YI, Chang JS, Ko H, et al. Development and Validation of a Normal Tissue Complication Probability Model for Lymphedema After Radiation Therapy in Breast Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 36739918. doi:10.1016/j.ijrobp.2023.01.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。